Public Advocacy
DiscoverTME strives for a world where cutting-edge therapies that improve human health are accessible to all people.
How are others thinking about the reconciling of accessibility and cost of biomedical innovations?
Accessibility
Biomedical
innovation
Note: Posting of a resource on this page does not imply endorsement of any of its content. Nor do we receive any form of compensation for their mention.
What we are reading (or have read)
2026
July 5 — Just got a copy of Pharma Monopoly: The Battle for the Future of Mediciness, by Tahir Amin and Rohit Malpani. A critical examination of the promise and pitfalls of the current patent ecosystem in pharma. Will make for an interesting read!
March 18 — We learned about the Walter and Eliza Hall Institute of Medical Research in Australia, and their foudning of the national Drug Discovery Centre (link). This gives researchers access to ultra-high throughput drug screens to leverage emerging discoveries towards therapeutics development.
2024
July 11 —
Featured in this month's I-MAK (link) newsletter: a series of updates on legislation and proposals trying to balance intellectual property protection with drug accessibility.
June 20 —
Back in 2009, Bernard Munos (now senior fellow @Milken Institute) published an insightful analysis of the evolution of the pharmaceutical development landscape. (Nature Reviews Drug Discovery - link). He ends with some hopeful and thought-provoking ideas for a future where innovative therapies can more easily be delivered to patients.
May 7 —
We learned how Virginia Commonwealth University's Medicines for All Institute increases access to life-saving medications by developing and publishing optimized manufacturing processes.
February 26 —
The Price of Health (by Michael Kinch and Lori Weiman) is a great starting point to understand the complexity of the problem.
This is a widely available, popular book describing the origins of pharmaceutical development and how its evolution has affected the cost of novel medications.
